推动生物标志物在肾移植中的临床转化
肾移植长期结局仍不理想,现有免疫抑制治疗调整依赖经验性时机或发现损伤后证据,难以在显著损伤前识别排斥、慢性亚临床炎症及个体化免疫机制。本文综述功能T细胞检测、尿液基因与蛋白检测、外周血细胞基因表达谱及移植物基因表达谱等候选生物标志物的数据,指出临床应用的障碍并提出推动个体化移植管理从研究假设走向临床实施的策略。
要点
- 现有免疫抑制调整策略常在显著损伤发生后才识别排斥,且无法检测慢性亚临床炎症。
- 功能T细胞检测、尿液基因与蛋白检测、外周血及移植物基因表达谱是潜力较高的候选生物标志物。
- 作者提出将基于生物标志物的个体化移植管理从研究假设推向临床实施的策略。
核心结论
- 可靠量化或预测移植物损伤风险的检测与生物标志物有望克服现有策略的不足,帮助临床医生优化免疫抑制方案。
研究设计与样本
- 综述,汇总功能T细胞检测、尿液基因与蛋白检测、外周血细胞基因表达谱及移植物基因表达谱等候选生物标志物的数据。
主要发现
- 现有免疫抑制治疗虽有效,但剂量调整常规基于移植后时间经验性进行,或根据肾功能异常、组织学移植物损伤证据或感染而改变。
- 此类策略往往在显著损伤已发生后才检测到移植物排斥,无法检测可负面影响移植物存活的慢性亚临床炎症,并忽略移植受者间差异贡献于移植物损伤的特定风险与免疫机制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Long-term kidney transplant outcomes remain suboptimal, delineating an unmet medical need. Although current immunosuppressive therapy in kidney transplant recipients is effective, dosing is conventionally adjusted empirically on the basis of time after transplant or altered in response to detection of kidney dysfunction, histologic evidence of allograft damage, or infection. Such strategies tend to detect allograft rejection after significant injury has already occurred, fail to detect chronic subclinical inflammation that can negatively affect graft survival, and ignore specific risks and immune mechanisms that differentially contribute to allograft damage among transplant recipients. Assays and biomarkers that reliably quantify and/or predict the risk of allograft injury have the potential to overcome these deficits and thereby, aid clinicians in optimizing immunosuppressive regimens. Herein, we review the data on candidate biomarkers that we contend have the highest potential to become clinically useful surrogates in kidney transplant recipients, including functional T cell assays, urinary gene and protein assays, peripheral blood cell gene expression profiles, and allograft gene expression profiles. We identify barriers to clinical biomarker adoption in the transplant field and suggest strategies for moving biomarker-based individualization of transplant care from a research hypothesis to clinical implementation.
引用
- Menon MC, Murphy B, Heeger PS, et al. Moving Biomarkers toward Clinical Implementation in Kidney Transplantation. J Am Soc Nephrol. 2017. PMID: 28062570. doi:10.1681/ASN.2016080858
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。